Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson 3Q

Worldwide Pharmaceutical sales were $5.5 billion in the quarter (+5%), with operational growth of 6% and a negative impact from currency of 1%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 3Q

3Q Revenues: $15.0 billion (-1%)

3Q Earnings: $3.4 billion (+2%)

YTD Revenue: $45.9 billion (+1%)

YTD Earnings: $11.4 billion (+13%)

Comments: Worldwide Pharmaceutical sales were $5.5 billion in the quarter (+5%), with operational growth of 6% and a negative impact from currency of 1%. Domestic and international sales were up 7% and 2%, respectively. Remicade sales were $1.2 billion in the quarter (+19%). Prezista sales were $230 million (+52%). Risperdal Consta sales were $378 million (+7%). Velcade sales were up 7% to $246 million. Procrit sales dropped 25% to $406 million. Risperdal sales were down 37% to $121 million. Topamax sales were down 27% to $127 million. Worldwide Consumer sales dropped 11% in the quarter to $3.6 billion, taking a hit from OTC product recalls including Tylenol and Motrin, along with the closure of a factory. Worldwide Medical Devices and Diagnostics sales were $5.9 billion (+1%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters